Adult growth hormone replacement: Current understanding

Current Opinion in Pharmacology

Volumn 3, Issue 6, 2003, Pages 642-649

  Murray, Robert D ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; CALCIUM; COPOLYMER; GROWTH HORMONE; GROWTH HORMONE SECRETAGOGUE; PLACEBO; RECOMBINANT DNA; SOMATOMEDIN C; TABIMORELIN; VITAMIN D;

ADULTHOOD; ARTHRALGIA; ARTICLE; BODY SURFACE; BODY WEIGHT; BONE MINERAL; CARDIOVASCULAR RISK; CLINICAL TRIAL; COLORECTAL CARCINOMA; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG FORMULATION; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; ERYTHEMA; FEMALE; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE RELEASE; HEADACHE; HODGKIN DISEASE; HORMONAL REGULATION; HORMONE SUBSTITUTION; HUMAN; HYPERINSULINEMIA; INJECTION PAIN; LOW DRUG DOSE; MALE; METASTASIS; MORTALITY; ONSET AGE; OSTEOPOROSIS; PATIENT ATTITUDE; PRIORITY JOURNAL; PROSTATE DISEASE; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; SKIN NODULE; TREATMENT OUTCOME; TUMOR RECURRENCE; VASCULAR ENDOTHELIUM;

EID: 0344444710     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2003.07.008     Document Type: Review

References (82)

1. Jorgensen J.O. Pedersen S.A. Thuesen L. Jorgensen J. Ingemann Hansen T. Skakkebaek N.E. Christiansen J.S. Beneficial effects of growth hormone treatment in GH-deficient adults Lancet 1 1989 1221-1225
2. Salomon F. Cuneo R.C. Hesp R. Sonksen P.H. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency N. Engl. J. Med. 321 1989 1797-1803
3. de Boer H. Blok G.J. Van der Veen E.A. Clinical aspects of growth hormone deficiency in adults Endocr. Rev. 16 1995 63-86
4. Carroll P.V. Christ E.R. Bengtsson B.A. Carlsson L. Christiansen J.S. Clemmons D. Hintz R. Ho K. Laron Z. Sizonenko P. et al. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Growth Hormone Research Society Scientific Committee J. Clin. Endocrinol. Metab. 83 1998 382-395
5. Kehely A. Bates P.C. Frewer P. Birkett M. Blum W.F. Mamessier P. Ezzat S. Ho K.K. Lombardi G. Luger A. et al. Short-term safety and efficacy of human GH replacement therapy in 595 adults with GH deficiency: a comparison of two dosage algorithms J. Clin. Endocrinol. Metab. 87 2002 1974-1979
6. Yuen K. Ong K. Husbands S. Chatelain P. Fryklund L. Gluckman P. Ranke M. Cook D. Rosenfeld R. Wass J. Dunger D. The effects of short-term administration of two low doses versus the standard GH replacement dose on insulin sensitivity and fasting glucose levels in young healthy adults J. Clin. Endocrinol. Metab. 87 2002 1989-1995
7. Florakis D. Hung V. Kaltsas G. Coyte D. Jenkins P.J. Chew S.L. Grossman A.B. Besser G.M. Monson J.P. Sustained reduction in circulating cholesterol in adult hypopituitary patients given low dose titrated growth hormone replacement therapy: a two year study Clin. Endocrinol. (Oxf) 53 2000 453-459
8. Drake W.M. Coyte D. Camacho Hubner C. Jivanji N.M. Kaltsas G. Wood D.F. Trainer P.J. Grossman A.B. Besser G.M. Monson J.P. Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults J. Clin. Endocrinol. Metab. 83 1998 3913-3919
9. Ekman B. Lindstrom T. Nystrom F. Olsson A.G. Toss G. Arnqvist H.J. A dose titration model for recombinant GH substitution aiming at normal plasma concentrations of IGF-I in hypopituitary adults Eur. J. Endocrinol. 147 2002 49-57
10. Murray R.D. Wieringa G.E. Lissett C.A. Darzy K.H. Smethurst L.E. Shalet S.M. Low-dose GH replacement improves the adverse lipid profile associated with the adult GH deficiency syndrome Clin. Endocrinol. (Oxf) 56 2002 525-532
11. Murray R.D. Darzy K.H. Gleeson H.K. Shalet S.M. GH-deficient survivors of childhood cancer: GH replacement during adult life J. Clin. Endocrinol. Metab. 87 2002 129-135
12. Murray R.D. Skillicorn C.J. Howell S.J. Lissett C.A. Rahim A. Shalet S.M. Dose titration and patient selection increases the efficacy of GH replacement in GHD adults Clin. Endocrinol. (Oxf) 50 1999 749-757
13. Randeva H.S. Murray R.D. Lewandowski K.C. O'Callaghan C.J. Horn R. O'Hare P. Brabant G. Hillhouse E.W. Shalet S.M. Differential effects of GH replacement on the components of the leptin system in GH-deficient individuals J. Clin. Endocrinol. Metab. 87 2002 798-804
14. Ahmad A.M. Hopkins M.T. Weston P.J. Fraser W.D. Vora J.P. Effects of GH replacement on 24-h ambulatory blood pressure and its circadian rhythm in adult GH deficiency Clin. Endocrinol. (Oxf) 56 2002 431-437
15. Ahmad A.M. Hopkins M.T. Thomas J. Ibrahim H. Fraser W.D. Vora J.P. Body composition and quality of life in adults with growth hormone deficiency; effects of low-dose growth hormone replacement Clin. Endocrinol. (Oxf) 54 2001 709-717
16. Ahmad A.M. Guzder R. Wallace A.M. Thomas J. Fraser W.D. Vora J.P. Circadian and ultradian rhythm and leptin pulsatility in adult GH deficiency: effects of GH replacement J. Clin. Endocrinol. Metab. 86 2001 3499-3506
17. Ekman B. Ohman P.K. Arnqvist H.J. Lindstrom T. Nystrom F.H. Individualized growth hormone substitution with normalized IGF-I levels does not stimulate the renin-angiotensin-aldosterone system Clin. Endocrinol. (Oxf) 57 2002 473-479
18. Murray R.D. Adams J.E. Smethurst L.E. Shalet S.M. Spinal irradiation impairs the osteo-anabolic effects of low-dose growth hormone replacement in adults with childhood-onset GH deficiency Clin. Endocrinol. (Oxf) 56 2002 169-174
19. Attanasio A.F. Bates P.C. Ho K.K. Webb S.M. Ross R.J. Strasburger C.J. Bouillon R. Crowe B. Selander K. Valle D. Lamberts S.W. Human growth hormone replacement in adult hypopituitary patients: long-term effects on body composition and lipid status-3-year results from the HypoCCS Database J. Clin. Endocrinol. Metab. 87 2002 1600-1606
20. Attanasio A.F. Lamberts S.W. Matranga A.M. Birkett M.A. Bates P.C. Valk N.K. Hilsted J. Bengtsson B.A. Strasburger C.J. Adult growth hormone (GH)-deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment. Adult Growth Hormone Deficiency Study Group J. Clin. Endocrinol. Metab. 82 1997 82-88
21. Murray R.D. Skillicorn C.J. Howell S.J. Lissett C.A. Rahim A. Smethurst L.E. Shalet S.M. Influences on quality of life in GH deficient adults and their effect on response to treatment Clin. Endocrinol. (Oxf) 51 1999 565-573
22. Murray R.D. Howell S.J. Lissett C.A. Shalet S.M. Pre-treatment IGF-I level is the major determinant of GH dosage in adult GH deficiency Clin. Endocrinol. (Oxf) 52 2000 537-542
23. Burman P. Johansson A.G. Siegbahn A. Vessby B. Karlsson F.A. Growth hormone (GH)-deficient men are more responsive to GH replacement therapy than women J. Clin. Endocrinol. Metab. 82 1997 550-555
24. White H.D. Ahmad A.M. Guzder R. Wallace A.M. Fraser W.D. Vora J.P. Gender variation in leptin circadian rhythm and pulsatility in adult growth hormone deficiency: effects of growth hormone replacement Clin. Endocrinol. (Oxf) 58 2003 482-488
25. Johansson A.G. Engstrom B.E. Ljunghall S. Karlsson F.A. Burman P. Gender differences in the effects of long term growth hormone (GH) treatment on bone in adults with GH deficiency J. Clin. Endocrinol. Metab. 84 1999 2002-2007
26. Ezzat S. Fear S. Gaillard R.C. Gayle C. Landy H. Marcovitz S. Mattioni T. Nussey S. Rees A. Svanberg E. Gender-specific responses of lean body composition and non-gender-specific cardiac function improvement after GH replacement in GH-deficient adults J. Clin. Endocrinol. Metab. 87 2002 2725-2733
27. Iranmanesh A. Lizarralde G. Veldhuis J.D. Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and the half-life of endogenous GH in healthy men J. Clin. Endocrinol. Metab. 73 1991 1081-1088
28. Attanasio A.F. Howell S. Bates P.C. Frewer P. Chipman J. Blum W.F. Shalet S.M. Body composition, IGF-I and IGFBP-3 concentrations as outcome measures in severely GH-deficient (GHD) patients after childhood GH treatment: a comparison with adult onset GHD patients J. Clin. Endocrinol. Metab. 87 2002 3368-3372
29. de Boer H. Blok G.J. van Lingen A. Teule G.J. Lips P. van der Veen E.A. Consequences of childhood-onset growth hormone deficiency for adult bone mass J. Bone Miner. Res. 9 1994 1319-1326
30. Kaufman J.M. Taelman P. Vermeulen A. Vandeweghe M. Bone mineral status in growth hormone-deficient males with isolated and multiple pituitary deficiencies of childhood onset J. Clin. Endocrinol. Metab. 74 1992 118-123
31. O'Halloran D.J. Tsatsoulis A. Whitehouse R.W. Holmes S.J. Adams J.E. Shalet S.M. Increased bone density after recombinant human growth hormone (GH) therapy in adults with isolated GH deficiency J. Clin. Endocrinol. Metab. 76 1993 1344-1348
32. Holmes S.J. Economou G. Whitehouse R.W. Adams J.E. Shalet S.M. Reduced bone mineral density in patients with adult onset growth hormone deficiency J. Clin. Endocrinol. Metab. 78 1994 669-674
33. Janssen Y.J. Hamdy N.A. Frolich M. Roelfsema F. Skeletal effects of two years of treatment with low physiological doses of recombinant human growth hormone (GH) in patients with adult-onset GH deficiency J. Clin. Endocrinol. Metab. 83 1998 2143-2148
34. Abrahamsen B. Hangaard J. Horn H.C. Hansen T.B. Gregersen G. Hansen-Nord M. Vahl N. Junker P. Andersen M. Hagen C. Evaluation of the optimum dose of growth hormone (GH) for restoring bone mass in adult-onset GH deficiency: results from two 12-month randomized studies Clin Endocrinol (Oxf) 57 2002 273-281
35. Murray RD, Columb B, Adams JE, Shalet SM: The osteopenia of adult GH deficiency is age-dependent [abstract]. British Endocrine Societies Annual Meeting, Belfast, 2001:P107.
36. Johannsson G. Rosen T. Bosaeus I. Sjostrom L. Bengtsson B.A. Two years of growth hormone (GH) treatment increases bone mineral content and density in hypopituitary patients with adult-onset GH deficiency J. Clin. Endocrinol. Metab. 81 1996 2865-2873
37. Kann P. Piepkorn B. Schehler B. Andreas J. Lotz J. Prellwitz W. Beyer J. Effect of long-term treatment with GH on bone metabolism, bone mineral density and bone elasticity in GH-deficient adults Clin. Endocrinol. (Oxf) 48 1998 561-568
38. Sneppen S.B. Hoeck H.C. Kollerup G. Sorensen O.H. Laurberg P. Feldt-Rasmussen U. Bone mineral content and bone metabolism during physiological GH treatment in GH-deficient adults - an 18-month randomised, placebo-controlled, double blinded trial Eur. J. Endocrinol. 146 2002 187-195
39. Vandeweghe M. Taelman P. Kaufman J.M. Short and long-term effects of growth hormone treatment on bone turnover and bone mineral content in adult growth hormone-deficient males Clin. Endocrinol. (Oxf) 39 1993 409-415
40. Drake W.M. Carroll P.V. Maher K.T. Metcalfe K.A. Camacho-Hubner C. Shaw N.J. Dunger D.B. Cheetham T.D. Savage M.O. Monson J.P. The effect of cessation of growth hormone (GH) therapy on bone mineral accretion in GH-deficient adolescents at the completion of linear growth J. Clin. Endocrinol. Metab. 88 2003 1658-1663
41. Cuneo R.C. Judd S. Wallace J.D. Perry Keene D. Burger H. Lim Tio S. Strauss B. Stockigt J. Topliss D. Alford F. et al. The Australian multicenter trial of growth hormone (GH) treatment in GH-deficient adults J. Clin. Endocrinol. Metab. 83 1998 107-116
42. Baum H.B. Biller B.M. Finkelstein J.S. Cannistraro K.B. Oppenhein D.S. Schoenfeld D.A.Michel T.H.Wittink H.Klibanski A.Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency. a randomized, placebo-controlled trial Ann. Intern. Med. 125 1996 883-890
43. Marcus R. Recombinant human growth hormone as potential therapy for osteoporosis Baillieres Clin. Endocrinol. Metab. 12 1998 251-260
44. Saaf M. Hilding A. Thoren M. Troell S. Hall K. Growth hormone treatment of osteoporotic postmenopausal women - a one-year placebo-controlled study Eur. J. Endocrinol. 140 1999 390-399
45. Brill K.T. Weltman A.L. Gentili A. Patrie J.T. Fryburg D.A. Hanks J.B. Urban R.J. Veldhuis J.D. Single and combined effects of growth hormone and testosterone administration on measures of body composition, physical performance, mood, sexual function, bone turnover, and muscle gene expression in healthy older men J. Clin. Endocrinol. Metab. 87 2002 5649-5657
46. Sugimoto T. Kaji H. Nakaoka D. Yamauchi M. Yano S. Sugishita T. Baylink D.J. Mohan S. Chihara K. Effect of low-dose of recombinant human growth hormone on bone metabolism in elderly women with osteoporosis Eur. J. Endocrinol. 147 2002 339-348
47. Rudman D. Feller A.G. Nagraj H.S. Gergans G.A. Lalitha P.Y. Goldberg A.F. Schlenker R.A. Cohn L. Rudman I.W. Mattson D.E. Effects of human growth hormone in men over 60 years old N. Engl. J. Med. 323 1990 1-6
48. Gillberg P. Mallmin H. Petren-Mallmin M. Ljunghall S. Nilsson A.G. Two years of treatment with recombinant human growth hormone increases bone mineral density in men with idiopathic osteoporosis J. Clin. Endocrinol. Metab. 87 2002 4900-4906
49. Ueland T. Bollerslev J. Flyvbjerg A. Hansen T.B. Vahl N. Mosekilde L. Effects of 12 months of GH treatment on cortical and trabecular bone content of IGFs and OPG in adults with acquired GH deficiency: a double-blind, randomized, placebo-controlled study J. Clin. Endocrinol. Metab. 87 2002 2760-2763
50. Lanzi R. Losa M. Villa I. Gatti E. Sirtori M. Dal Fiume C. Rubinacci A. GH replacement therapy increases plasma osteoprotegerin levels in GH-deficient adults Eur. J. Endocrinol. 148 2003 185-191
51. Colao A. di Somma C. Pivonello R. Cuocolo A. Spinelli L. Bonaduce D. Salvatore M. Lombardi G. The cardiovascular risk of adult GH deficiency (GHD) improved after GH replacement and worsened in untreated GHD: a 12-month prospective study J. Clin. Endocrinol. Metab. 87 2002 1088-1093
52. Smith J.C. Evans L.M. Wilkinson I. Goodfellow J. Cockcroft J.R. Scanlon M.F. Davies J.S.Effects of GH replacement on endothelial function and large-artery stiffness in GH-deficient adults: a randomized, double-blind, placebo-controlled study Clin. Endocrinol. (Oxf) 56 2002 493-501
53. Smith J.C. Lang D. McEneny J. Evans L.M. Scanlon M.F. Young I. Davies J. Effects of GH on lipid peroxidation and neutrophil superoxide anion-generating capacity in hypopituitary adults with GH deficiency Clin. Endocrinol. (Oxf) 56 2002 449-455
54. Gleeson H.K. Souza A.H. Gill M.S. Wieringa G.E. De A.B.E.S. Barretto-Filho J.A. Shalet S.M. Aguiar-Oliveira M.H. Clayton P.E. Lipid profiles in untreated severe congenital isolated growth hormone deficiency through the lifespan Clin. Endocrinol. (Oxf) 57 2002 89-95
55. Leonsson M. Hulthe J. Oscarsson J. Johannsson G. Wendelhag I. Wikstrand J. Bengtsson B.A. Intima-media thickness in cardiovascularly asymptomatic hypopituitary adults with growth hormone deficiency: relation to body mass index, gender, and other cardiovascular risk factors Clin. Endocrinol. (Oxf) 57 2002 751-759
56. Rosen T. Bengtsson B.A. Premature mortality due to cardiovascular disease in hypopituitarism Lancet 336 1990 285-288
57. Tomlinson J.W. Holden N. Hills R.K. Wheatley K. Clayton R.N. Bates A.S. Sheppard M.C. Stewart P.M. Association between premature mortality and hypopituitarism. West Midlands prospective hypopituitary study group Lancet 357 2001 425-431
58. Bramnert M. Segerlantz M. Laurila E. Daugaard J.R. Manhem P. Groop L. Growth hormone replacement therapy induces insulin resistance by activating the glucose-fatty acid cycle J. Clin. Endocrinol. Metab. 88 2003 1455-1463
59. Twickler T.B. Dallinga-Thie G.M. Visseren F.L. de Vries W.R. Erkelens D.W. Koppeschaar H.P. Induction of postprandial inflammatory response in adult onset growth hormone deficiency is related to plasma remnant-like particle-cholesterol concentration J. Clin. Endocrinol. Metab. 88 2003 1228-1233
60. Scott E.M. Greenwood J.P. Stoker J.B. Mary D.A. Gilbey S.G. Sympathetic nerve hyperactivity is associated with increased peripheral vascular resistance in hypopituitary patients with growth hormone deficiency Clin. Endocrinol. (Oxf) 56 2002 759-763
61. Smith J.C. Lane H.A. Lewis J. Dann S. Goodfellow J. Collins P. Evans L.M. Scanlon M.F. Davies J.S. Endothelial function and coagulant factors in growth hormone-treated hypopituitary adults receiving desmopressin J. Clin. Endocrinol. Metab. 88 2003 2152-2156
62. Hana V. Prazny M. Marek J. Skrha J. Justova V. Reduced microvascular perfusion and reactivity in adult GH deficient patients is restored by GH replacement Eur. J. Endocrinol. 147 2002 333-337
63. Oomen P.H. Beentjes J.A. Bosma E. Smit A.J. Reitsma W.D. Dullaart R.P. Reduced capillary permeability and capillary density in the skin of GH-deficient adults: improvement after 12 months GH replacement Clin. Endocrinol. (Oxf) 56 2002 519-524
64. Svensson J. Stibrant Sunnerhagen K. Johannsson G. Five years of growth hormone replacement therapy in adults: age- and gender-related changes in isometric and isokinetic muscle strength J. Clin. Endocrinol. Metab. 88 2003 2061-2069
65. Svensson J. Fowelin J. Landin K. Bengtsson B.A. Johansson J.O. Effects of seven years of GH-replacement therapy on insulin sensitivity in GH-deficient adults J. Clin. Endocrinol. Metab. 87 2002 2121-2127
66. Gilchrist F.J. Murray R.D. Shalet S.M. The effect of long-term untreated growth hormone deficiency (GHD) and 9 years of GH replacement on the quality of life (QoL) of GH-deficient adults Clin. Endocrinol. (Oxf) 57 2002 363-370
67. Gibney J. Wallace J.D. Spinks T. Schnorr L. Ranicar A. Cuneo R.C. Lockhart S. Burnand K.G. Salomon F. Sonksen P.H. Russell-Jones D. The effects of 10 years of recombinant human growth hormone (GH) in adult GH-deficient patients J. Clin. Endocrinol. Metab. 84 1999 2596-2602
68. Chrisoulidou A. Beshyah S.A. Rutherford O. Spinks T.J. Mayet J. Kyd P. Anyaoku V. Haida A. Ariff B. Murphy M. et al. Effects of 7 years of growth hormone replacement therapy in hypopituitary adults J. Clin. Endocrinol. Metab. 85 2000 3762-3769
69. Christ E.R. Simpson H.L. Breen L. Sonksen P.H. Russell-Jones D.L. Kohner E.M. The effect of growth hormone (GH) replacement therapy in adult patients with type 1 diabetes mellitus and GH deficiency Clin. Endocrinol. (Oxf) 58 2003 309-315
70. Hankinson S.E. Willett W.C. Colditz G.A. Hunter D.J. Michaud D.S. Deroo B. Rosner B. Speizer F.E. Pollak M. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer Lancet 351 1998 1393-1396
71. Chan J.M. Stampfer M.J. Giovannucci E. Gann P.H. Ma J. Wilkinson P. Hennekens C.H. Pollak M. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study Science 279 1998 563-566
72. Jenkins P.J. Fairclough P.D. Richards T. Lowe D.G. Monson J. Grossman A. Wass J.A. Besser M. Acromegaly, colonic polyps and carcinoma Clin. Endocrinol. (Oxf) 47 1997 17-22
73. Swerdlow A.J. Higgins C.D. Adlard P. Preece M.A. Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959-85: a cohort study Lancet 360 2002 273-277
74. le Roux C.W. Jenkins P.J. Chew S.L. Camacho-Hubner C. Grossman A.B. Besser G.M. Monson J.P. Growth hormone replacement does not increase serum prostate-specific antigen in hypopituitary men over 50 years Eur. J. Endocrinol. 147 2002 59-63
75. Colao A. Di Somma C. Spiezia S. Filippella M. Pivonello R. Lombardi G. Effect of growth hormone (GH) and/or testosterone replacement on the prostate in GH-deficient adult patients J. Clin. Endocrinol. Metab. 88 2003 88-94
76. Hatrick A.G. Boghalo P. Bingham J.B. Ayres A.B. Sonksen P.H. Russell-Jones D.L. Does GH replacement therapy in adult GH-deficient patients result in recurrence or increase in size of pituitary tumours? Eur. J. Endocrinol. 146 2002 807-811
77. Swerdlow A.J. Reddingius R.E. Higgins C.D. Spoudeas H.A. Phipps K. Qiao Z. Ryder W.D.J. Brada M. Hayward R.D. Brook C.G.D. et al. Growth hormone treatment of children with brain tumours and risk of tumor recurrence J. Clin. Endocrinol. Metab. 85 2000 4444-4449
78. Leung W. Rose S.R. Zhou Y. Hancock M.L. Burstein S. Schriock E.A. Lustig R. Danish R.K. Evans W.E. Hudson M.M. Pui C.H. Outcomes of growth hormone replacement therapy in survivors of childhood acute lymphoblastic leukemia J. Clin. Oncol. 20 2002 2959-2964
79. Svensson J. Monson J.P. Vetter T. Hansen T.K. Savine R. Kann P. Bex M. Reincke M. Hagen C. Beckers A. et al. Oral administration of the growth hormone secretagogue NN703 in adult patients with growth hormone deficiency Clin. Endocrinol. (Oxf) 58 2003 572-580
80. Rahim A. O'Neill P.A. Shalet S.M. Growth hormone status during long-term hexarelin therapy J. Clin. Endocrinol. Metab. 83 1998 1644-1649
81. Reiter E.O. Attie K.M. Moshang Jr. T. Silverman B.L. Kemp S.F.Neuwirth R.B. Ford K.M. Saenger P. A multicenter study of the efficacy and safety of sustained release GH in the treatment of naive pediatric patients with GH deficiency J. Clin. Endocrinol. Metab. 86 2001 4700-4706
82. Cook D.M. Biller B.M. Vance M.L. Hoffman A.R. Phillips L.S. Ford K.M. Benziger D.P. Illeperuma A. Blethen S.L. Attie K.M. et al. The pharmacokinetic and pharmacodynamic characteristics of a long-acting growth hormone (GH) preparation (nutropin depot) in GH-deficient adults J. Clin. Endocrinol. Metab. 87 2002 4508-4514